Plasma proteomic signatures in bipolar disorder and their implications for data-driven patient stratification
Abstract
Bipolar disorder (BD) is a heterogeneous mood disorder that lacks robust biomarkers for biological stratification. We used high-throughput plasma proteomics to characterize case-control differences, identify proteomic subgroups within BD, and examine their associations with blood-based markers and clinical features. Plasma samples from the French I-GIVE (Immuno-Genetics, Inflammation, retroVirus, Environment) cohort, including 248 participants with BD and 76 healthy controls, were assessed using the Olink Reveal panel (1,034 proteins). Age-, sex-, and BMI-adjusted case-control analyses identified 527 differentially expressed proteins in the imputed analysis and 136 in the complete-case analysis, with high agreement in effect estimates and involvement of immune, metabolic, oxidative stress, and endothelial-related processes. Despite the large number of differentially expressed proteins, pathway enrichment was limited to B-cell receptor and chronic myeloid leukemia-related signaling in BD. Unsupervised clustering within BD identified two proteomic subgroups, with enrichment between clusters in longevity-regulating pathways, cellular senescence, FLT3 signaling, and transcription-related pathways. Among four measured inflammatory/endothelial markers, serum amyloid A was the only marker showing a significant difference between groups (FDR < 0.05). Clinical characteristics were similar across clusters, although childhood physical abuse and a greater somatic comorbidity burden were associated with the subgroup showing higher protein abundance. Our findings support biological heterogeneity within BD and suggest that proteomic subgrouping may capture variation not evident in pooled case-control analyses.
Related
- Convergent and Distinct Transcriptional Signatures in Suicide, Bipolar Disorder, and Major Depressive Disorder
- Proteomic profiling of baseline CSF and serum from HDClarity identifies signatures for Huntington disease staging and stratification
- Use of Integrative Proteomic Analysis to Uncover Shared Molecular Signatures Across Distinct Forms of Hydrocephalus
- Ultrastructural and Proteomic Signatures of Mechanoadaptive Fibroblast Remodeling across Microphysiological and Mesoscale Shear Platforms
- Stage-specific proteomic signatures of synaptopathy in Alzheimers disease
BibTeX
@article{pedrazpetrozzi2026plasma,
title = {{Plasma proteomic signatures in bipolar disorder and their implications for data-driven patient stratification}},
author = {Bruno Pedraz-Petrozzi and Wahid Boukouaci and Ophélia Godin and Jérémy Bernard and Lauren Hasty and Jean-Romain Richard and Caroline Barau and Philippe Le Corvoisier and Pierre Solomon and Jeremie Poschmann and Moritz Spangemacher and Robert Dantzer and Andreas Meyer-Lindenberg and Husseini Manji and Golam M Khandaker and Marion Leboyer},
journal = {Brain, Behavior, and Immunity},
year = {2026},
month = oct,
doi = {10.1016/j.bbi.2026.107071},
url = {https://inserm.hal.science/inserm-05803551v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Plasma proteomic signatures in bipolar disorder and their implications for data-driven patient stratification
AU - Bruno Pedraz-Petrozzi
AU - Wahid Boukouaci
AU - Ophélia Godin
AU - Jérémy Bernard
AU - Lauren Hasty
AU - Jean-Romain Richard
AU - Caroline Barau
AU - Philippe Le Corvoisier
AU - Pierre Solomon
AU - Jeremie Poschmann
AU - Moritz Spangemacher
AU - Robert Dantzer
AU - Andreas Meyer-Lindenberg
AU - Husseini Manji
AU - Golam M Khandaker
AU - Marion Leboyer
PY - 2026
DA - 2026/10/16
JO - Brain, Behavior, and Immunity
DO - 10.1016/j.bbi.2026.107071
UR - https://inserm.hal.science/inserm-05803551v1
AB - Bipolar disorder (BD) is a heterogeneous mood disorder that lacks robust biomarkers for biological stratification. We used high-throughput plasma proteomics to characterize case-control differences, identify proteomic subgroups within BD, and examine their associations with blood-based markers and clinical features. Plasma samples from the French I-GIVE (Immuno-Genetics, Inflammation, retroVirus, Environment) cohort, including 248 participants with BD and 76 healthy controls, were assessed using the Olink Reveal panel (1,034 proteins). Age-, sex-, and BMI-adjusted case-control analyses identified 527 differentially expressed proteins in the imputed analysis and 136 in the complete-case analysis, with high agreement in effect estimates and involvement of immune, metabolic, oxidative stress, and endothelial-related processes. Despite the large number of differentially expressed proteins, pathway enrichment was limited to B-cell receptor and chronic myeloid leukemia-related signaling in BD. Unsupervised clustering within BD identified two proteomic subgroups, with enrichment between clusters in longevity-regulating pathways, cellular senescence, FLT3 signaling, and transcription-related pathways. Among four measured inflammatory/endothelial markers, serum amyloid A was the only marker showing a significant difference between groups (FDR < 0.05). Clinical characteristics were similar across clusters, although childhood physical abuse and a greater somatic comorbidity burden were associated with the subgroup showing higher protein abundance. Our findings support biological heterogeneity within BD and suggest that proteomic subgrouping may capture variation not evident in pooled case-control analyses.
SN - 0889-1591
SN - 1090-2139
ER -